June 20, 2016 10:16am
Unlike conventional, non-integrating AAV gene therapy that has the “potential to wash out” over time as the patient's liver cells divide and turn over, SB-913 has the potential to provide a uniquely durable solution through genome editing. A wing and a prayer!
Members only. Please login.